Science & Technology

CDSCO Issues Alert to States Regarding Counterfeit Batches of Rabies Vaccine

06 September 2026UPSCSSCBank

In Brief

Issues countrywide alert against counterfeit rabies vaccine batches circulating in domestic markets.

The Central Drugs Standard Control Organisation (CDSCO), India’s apex drug regulatory authority, issued an urgent countrywide alert to all State Drug Controllers regarding counterfeit batches of anti-rabies vaccines detected in domestic distribution channels. CDSCO confirmed that the compromised batch was manufactured fraudulently under a licensed brand name and verified that none of the counterfeit units were exported overseas.

CDSCO operates under the Directorate General of Health Services within the Ministry of Health and Family Welfare, deriving regulatory powers from the Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945. The regulator is responsible for approving new drugs, conducting clinical trials, setting standards for drug quality, and coordinating state-level drug enforcement to prevent spurious, adulterated, or misbranded pharmaceuticals.

Rabies is a fatal viral zoonotic disease caused by Lyssavirus, transmitted primarily through bites of infected animals like dogs. Post-Exposure Prophylaxis (PEP), consisting of anti-rabies vaccine and rabies immunoglobulin, is 100% effective when administered promptly. India accounts for nearly 36% of global rabies deaths, making the integrity of the domestic anti-rabies supply chain critical to achieving the National Action Plan for Dog Mediated Rabies Elimination (NAPRE) by 2030.

This story bridges Public Health, Regulatory Policy, and Science & Technology. Prelims questions frequently target the statutory basis of CDSCO, the Drugs and Cosmetics Act 1940, viral vector diseases, and NAPRE 2030 targets. Mains GS-Paper II questions on health governance will examine regulatory gaps in pharmaceutical supply chain integrity, track-and-trace QR code enforcement, and public health security against counterfeit medications.

UPSC Study NotesHIGHGS2 — Health & Public Health Policy | GS3 — Science & Technology | Prelims

GS2 — Health & Public Health Policy | GS3 — Science & Technology | Prelims

📌 Exam Angle

Prelims: MCQ on CDSCO's statutory powers under Drugs and Cosmetics Act 1940, or identification of rabies as a zoonotic disease requiring PEP. Mains: Essay/case study on regulatory gaps in pharmaceutical supply chain integrity, counterfeit drug enforcement mechanisms, and India's progress toward NAPRE 2030 elimination targets—linking public health security to governance failures.

⚠️ Key Concerns

Counterfeit drug circulation exposes critical gaps in track-and-trace enforcement and cold-chain monitoring despite CDSCO oversight. The burden—36% of global rabies deaths in India—reflects weak last-mile enforcement by State Drug Controllers and inadequate interagency coordination. Post-exposure prophylaxis efficacy depends on vaccine authenticity; counterfeit batches undermine NAPRE 2030's elimination goal and create public health crises.

💡 Why It Matters

Counterfeit pharmaceuticals directly threaten India's health security and SDG commitments on disease elimination. This incident exposes regulatory fragmentation between central and state authorities, demanding urgent capacity-building and digitalization of pharmaceutical supply chains.

🔑 Must Remember

• CDSCO derives regulatory authority from Drugs and Cosmetics Act 1940 and Rules 1945. • Rabies is 100% preventable via timely Post-Exposure Prophylaxis (PEP); India bears 36% of global rabies deaths. • NAPRE targets rabies elimination by 2030 through dog-mediated prevention strategies.

📝 Key Terms

CDSCODrugs and Cosmetics Act 1940spurious drugsPost-Exposure Prophylaxiszoonotic diseasesNAPRE 2030pharmaceutical supply chaindrug regulatory authority

CDSCO Issues Alert to States Regarding Counterfeit Batches of Rabies Vaccine

More in Science & Technology